GLP-1s Aren’t Just Weight-Loss Drugs Anymore

GLP-1 medications changed obesity treatment—but the number on the scale may be only part of the story. In this episode, Dr. Albert Takem explains why medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are increasingly part of much broader medical conversations. For appropriately selected patients, treatment may involve not only obesity and diabetes, but cardiovascular risk, chronic kidney disease, obstructive sleep apnea, and long-term metabolic health. We discuss:  Why obesity treatment should not be viewed as purely cosmetic  What the SELECT trial showed about semaglutide and major cardiovascular events  How GLP-1 therapy is changing the conversation around chronic kidney disease  Why Zepbound has entered the treatment landscape for obstructive sleep apnea in certain adults with obesity  How GLP-1 medications affect insulin, glucagon, gastric emptying, and appetite  How much of the benefit may come from weight loss itself—and what researchers are still studying  Why GLP-1 medications are neither “miracle drugs” nor “cheating”  Common side effects, appropriate monitoring, and why these medications require medical supervision  Why patients should track blood pressure, blood sugar, kidney function, sleep, physical function, and other health markers—not only body weight  The importance of nutrition, protein, exercise, sleep, and a long-term treatment strategy alongside medication The scale may be the most visible thing changing. For the right patient, it may not be the most important thing changing.Questions for Dr. Takem and the team💡 Start your journey today with Maryland Primary Care & WellnessBook your consultation: https://www.maryland-primarycare.com/